These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29673717)

  • 1. Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
    Cai X; Sun L; Dai Y; Avraham Y; Liu C; Han J; Liu Y; Feng D; Huang W; Qian H
    Bioorg Med Chem; 2018 May; 26(9):2599-2609. PubMed ID: 29673717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
    Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
    Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.
    Li C; Cai X; Dai Y; Liu C; Bi X; Zhou J; Li Q; Sun L; Huang W; Hou Z; Qian H
    Bioorg Med Chem; 2019 Oct; 27(20):115070. PubMed ID: 31471103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity.
    Han J; Huang X; Sun L; Li Z; Qian H; Huang W
    Biochem Pharmacol; 2013 Jul; 86(2):297-308. PubMed ID: 23707756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
    Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
    Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.
    Bech EM; Martos-Maldonado MC; Wismann P; Sørensen KK; van Witteloostuijn SB; Thygesen MB; Vrang N; Jelsing J; Pedersen SL; Jensen KJ
    J Med Chem; 2017 Sep; 60(17):7434-7446. PubMed ID: 28771355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
    Miranda LP; Winters KA; Gegg CV; Patel A; Aral J; Long J; Zhang J; Diamond S; Guido M; Stanislaus S; Ma M; Li H; Rose MJ; Poppe L; Véniant MM
    J Med Chem; 2008 May; 51(9):2758-65. PubMed ID: 18412318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stapled and
    Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
    J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
    Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity.
    Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
    Eur J Pharm Sci; 2018 Oct; 123():111-123. PubMed ID: 30031858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
    Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
    Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential.
    Han J; Chen X; Wang Y; Fei Y; Zhou F; Zhang Y; Liu L; Si P; Fu J
    Biochem Pharmacol; 2017 Oct; 142():155-167. PubMed ID: 28668697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
    Han J; Sun L; Chu Y; Li Z; Huang D; Zhu X; Qian H; Huang W
    J Med Chem; 2013 Dec; 56(24):9955-68. PubMed ID: 24308627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
    Wismann P; Pedersen SL; Hansen G; Mannerstedt K; Pedersen PJ; Jeppesen PB; Vrang N; Fosgerau K; Jelsing J
    Physiol Behav; 2018 Aug; 192():72-81. PubMed ID: 29540315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
    Han J; Fu J; Yang Q; Zhou F; Chen X; Li C; Yin J
    Eur J Med Chem; 2020 Jul; 198():112389. PubMed ID: 32388115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.